Curis - Stock Price History | CRIS

Historical daily share price chart and data for Curis since 2021 adjusted for splits. The latest closing stock price for Curis as of October 26, 2021 is 6.81.
  • The all-time high Curis stock closing price was 121.90 on August 01, 2000.
  • The Curis 52-week high stock price is 17.40, which is 155.5% above the current share price.
  • The Curis 52-week low stock price is 1.06, which is 84.4% below the current share price.
  • The average Curis stock price for the last 52 weeks is 8.61.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Curis Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 1.6124 1.8500 8.2000 0.6343 8.1900 381.76%
2019 1.7260 0.8212 2.8300 0.7800 1.7000 146.45%
2018 2.2008 3.7105 4.9005 0.6201 0.6898 -80.29%
2017 9.8499 16.2000 16.6500 3.4500 3.5000 -77.27%
2016 10.3843 13.8000 18.5000 6.4000 15.4000 5.84%
2015 13.3708 7.4000 18.6250 6.4500 14.5500 94.00%
2014 9.9855 14.3500 16.7000 5.6000 7.5000 -46.81%
2013 17.7888 18.3000 23.1500 12.3000 14.1000 -17.78%
2012 22.0877 22.7500 27.5000 15.1000 17.1500 -26.71%
2011 16.9551 10.1500 23.4000 10.1500 23.4000 136.36%
2010 11.0545 16.7500 18.0500 6.1500 9.9000 -39.08%
2009 8.4537 3.7750 17.3000 3.7750 16.2500 333.33%
2008 6.4607 5.1000 9.5000 3.4000 3.7500 -23.47%
2007 6.3478 6.2505 11.1000 4.5000 4.9000 -22.22%
2006 9.0609 18.8500 20.2500 4.7500 6.3000 -64.61%
2005 20.3896 25.1000 25.1000 16.3000 17.8000 -31.80%
2004 22.2705 22.8500 31.8000 12.6950 26.1000 16.00%
2003 15.3426 5.2000 28.5500 3.5500 22.5000 336.89%
2002 8.0832 27.0000 27.7500 2.7000 5.1500 -81.64%
2001 27.3305 41.8750 65.0000 15.6250 28.0500 -36.79%
2000 75.2167 121.9000 121.9000 34.5300 44.3750 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.624B $0.011B
Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86